Literature DB >> 29487418

HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia.

Amina M Abdul-Aziz1, Manar S Shafat1, Yu Sun1, Christopher R Marlein1, Rachel E Piddock1, Stephen D Robinson2, Dylan R Edwards1, Zhigang Zhou1, Angela Collins3, Kristian M Bowles1,3, Stuart A Rushworth4.   

Abstract

Approximately 80% of patients diagnosed with acute myeloid leukemia (AML) die as a consequence of failure to eradicate the tumor from the bone marrow microenvironment. We have recently shown that stroma-derived interleukin-8 (IL-8) promotes AML growth and survival in the bone marrow in response to AML-derived macrophage migration inhibitory factor (MIF). In the present study we show that high constitutive expression of MIF in AML blasts in the bone marrow is hypoxia-driven and, through knockdown of MIF, HIF1α and HIF2α, establish that hypoxia supports AML tumor proliferation through HIF1α signaling. In vivo targeting of leukemic cell HIF1α inhibits AML proliferation in the tumor microenvironment through transcriptional regulation of MIF, but inhibition of HIF2α had no measurable effect on AML blast survival. Functionally, targeted inhibition of MIF in vivo improves survival in models of AML. Here we present a mechanism linking HIF1α to a pro-tumoral chemokine factor signaling pathway and in doing so, we establish a potential strategy to target AML.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29487418     DOI: 10.1038/s41388-018-0151-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

Review 1.  Acute Myeloid Leukemia.

Authors:  Hartmut Döhner; Daniel J Weisdorf; Clara D Bloomfield
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

2.  HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia.

Authors:  Talia Velasco-Hernandez; Axel Hyrenius-Wittsten; Matilda Rehn; David Bryder; Jörg Cammenga
Journal:  Blood       Date:  2014-09-29       Impact factor: 22.113

Review 3.  Hematopoietic stem cells are regulated by Cripto, as an intermediary of HIF-1α in the hypoxic bone marrow niche.

Authors:  Kenichi Miharada; Göran Karlsson; Matilda Rehn; Emma Rörby; Kavitha Siva; Jörg Cammenga; Stefan Karlsson
Journal:  Ann N Y Acad Sci       Date:  2012-08       Impact factor: 5.691

Review 4.  Passing the baton: the HIF switch.

Authors:  Mei Yee Koh; Garth Powis
Journal:  Trends Biochem Sci       Date:  2012-07-18       Impact factor: 13.807

Review 5.  Normal and leukemic stem cell niches: insights and therapeutic opportunities.

Authors:  Koen Schepers; Timothy B Campbell; Emmanuelle Passegué
Journal:  Cell Stem Cell       Date:  2015-03-05       Impact factor: 24.633

6.  Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.

Authors:  Sujan Piya; Michael Andreeff; Gautam Borthakur
Journal:  Autophagy       Date:  2016-10-31       Impact factor: 16.016

7.  Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia.

Authors:  George Deeb; Mary M Vaughan; Ian McInnis; Laurie Ann Ford; Sheila N J Sait; Petr Starostik; Meir Wetzler; Terry Mashtare; Eunice S Wang
Journal:  Leuk Res       Date:  2010-12-21       Impact factor: 3.156

8.  How I treat acute myeloid leukemia.

Authors:  Jacob M Rowe; Martin S Tallman
Journal:  Blood       Date:  2010-06-17       Impact factor: 22.113

9.  Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

Authors:  Yin Wang; Yan Liu; Sami N Malek; Pan Zheng; Yang Liu
Journal:  Cell Stem Cell       Date:  2011-04-08       Impact factor: 24.633

10.  HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress.

Authors:  Kevin Rouault-Pierre; Lourdes Lopez-Onieva; Katie Foster; Fernando Anjos-Afonso; Isabelle Lamrissi-Garcia; Martin Serrano-Sanchez; Richard Mitter; Zoran Ivanovic; Hubert de Verneuil; John Gribben; David Taussig; Hamid Reza Rezvani; Frédéric Mazurier; Dominique Bonnet
Journal:  Cell Stem Cell       Date:  2013-10-03       Impact factor: 24.633

View more
  11 in total

1.  A novel immune prognostic model of non-M3 acute myeloid leukemia.

Authors:  Hong Ding; Yu Feng; Juan Xu; Zhimei Lin; Jingcao Huang; Fangfang Wang; Hongmei Luo; Yuhan Gao; Xinyu Zhai; Xin Wang; Li Zhang; Ting Niu; Yuhuan Zheng
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL.

Authors:  Pierre-Yves Dumas; Cécile Naudin; Séverine Martin-Lannerée; Brigitte Izac; Luana Casetti; Olivier Mansier; Benoît Rousseau; Alexandre Artus; Mélody Dufossée; Alban Giese; Pierre Dubus; Arnaud Pigneux; Vincent Praloran; Audrey Bidet; Arnaud Villacreces; Amélie Guitart; Noël Milpied; Olivier Kosmider; Isabelle Vigon; Vanessa Desplat; Isabelle Dusanter-Fourt; Jean-Max Pasquet
Journal:  Haematologica       Date:  2019-03-28       Impact factor: 9.941

3.  Targeting Thyrointegrin αvβ3 Using Fluorobenzyl Polyethylene Glycol Conjugated Tetraiodothyroacetic Acid (NP751) in Acute Myeloid Leukemia.

Authors:  Noureldien H E Darwish; Gennadi V Glinsky; Thangirala Sudha; Shaker A Mousa
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

4.  Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1α Inhibitor) and Dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells.

Authors:  Yuexian Zhang; Heng Chen; Yunfeng Shen; Xin Zhou
Journal:  J Immunol Res       Date:  2022-04-28       Impact factor: 4.493

Review 5.  The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities.

Authors:  Samantha Bruno; Manuela Mancini; Sara De Santis; Cecilia Monaldi; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

6.  Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.

Authors:  Adam J Lamble; Yoko Kosaka; Ted Laderas; Allie Maffit; Andy Kaempf; Lauren K Brady; Weiwei Wang; Nicola Long; Jennifer N Saultz; Motomi Mori; David Soong; Clare V LeFave; Fei Huang; Homer Adams; Marc M Loriaux; Cristina E Tognon; Pierrette Lo; Jeffrey W Tyner; Guang Fan; Shannon K McWeeney; Brian J Druker; Evan F Lind
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-08       Impact factor: 11.205

7.  Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model.

Authors:  Mateusz Rytelewski; Karine Harutyunyan; Natalia Baran; Saradhi Mallampati; M Anna Zal; Antonio Cavazos; Jason M Butler; Sergej Konoplev; Mirna El Khatib; Shane Plunkett; Joseph R Marszalek; Michael Andreeff; Tomasz Zal; Marina Konopleva
Journal:  Front Oncol       Date:  2020-06-30       Impact factor: 6.244

Review 8.  Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

Authors:  Eugenio Cavalli; Rosella Ciurleo; Maria Cristina Petralia; Paolo Fagone; Rita Bella; Katia Mangano; Ferdinando Nicoletti; Placido Bramanti; Maria Sofia Basile
Journal:  Molecules       Date:  2020-03-06       Impact factor: 4.411

9.  Network pharmacology-based strategy for predicting therapy targets of Tripterygium wilfordii on acute myeloid leukemia.

Authors:  Tingting Fang; Lanqin Liu; Wenjun Liu
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

Review 10.  Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development.

Authors:  Yiyi Yao; Fenglin Li; Jiansong Huang; Jie Jin; Huafeng Wang
Journal:  Exp Hematol Oncol       Date:  2021-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.